Canopy Growth vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Canopy Growth Corp (CGC)

Q3 202625 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

August 202625 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

Latest25 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.